Dr Reddys
Latest news, explainers and analysis on Dr Reddys. Tracking 3 stories on Arth Vani.
Connected in the graph
Latest on Dr Reddys
Dr Reddy's Pivots to Generic Semaglutide, Biosimilars for Future Growth
Dr Reddy's Laboratories is strategically focusing on the relaunch of generic semaglutide and expanding its biosimilars portfolio to drive future growth. This comes as the company navigates mixed results, with domestic formulations business growing but North American Revlimid sales declining in the September quarter.
Dr Reddy's Shares Drop 7% as Quality Issues Delay Weight-Loss Drug Launch
Shares of Dr Reddy’s Laboratories witnessed a sharp decline after the company paused commercial supplies of its semaglutide product. The delay stems from quality concerns regarding the active pharmaceutical ingredient (API) used in the drug.
Dr Reddy’s Shares Dip: What the Downturn Means for Your Pharma Portfolio
Shares of Dr. Reddy's Laboratories faced a decline today, reflecting a broader cooling off in pharmaceutical returns. Retail investors should monitor this Nifty 50 heavyweight as sector-specific volatility impacts both direct holdings and mutual fund NAVs.
Some listings may be sponsored and Arth Vani may earn a referral fee. All information is for educational purposes only — verify terms and suitability with the provider before acting. Not financial advice.